Life after failure of traditional androgen deprivation therapy.
Castrate resistant prostate cancer is a disease state which, counterintuitively, can be successfully treated with additional therapy directed at inhibition of androgen synthesis and/or interfering with the activity of the androgen receptor. Novel androgen biosynthesis inhibitors and antiandrogens are now being tested in large phase 3 clinical trials to clarify their role in the treatment of men who have failed traditional medical castration, with or without currently available nonsteroidal antiandrogens. A renewed interest in studying parenteral delivery of estrogens may provide evidence to revisit the initial medical therapy for advancing prostate cancer.
Eastern Virginia Medical School, Virginia Beach, VA 23464, USA. schellpf@evms.edu
Paul
P
Schellhammer
D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D011788:Quality of Life; D011944:Receptors, Androgen / Q000378:metabolism
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D011944:Receptors, Androgen